Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance
Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance
relmada therapeutics宣布对Reliance II三期研究的预先计划的中期分析显示，该研究是无效的，且不太可能以统计显著性达到主要疗效终点。
- Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants. No new safety signals were reported.
- The Data Monitoring Committee did not identify any new safety concerns
- Relmada to evaluate potential next steps for the REL-1017 program
- Relmada to continue to focus on the development of REL-P11 for metabolic disease
- Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024
- Reliance II旨在评估REL-1017作为重性抑郁障碍（MDD）的辅助治疗，可与其他已批准的抗抑郁药物联合使用。未报告新的安全信号。
- 数据监测委员会未发现任何新的安全问题。
- Relmada将评估REL-1017项目的潜在下一步措施。
- Relmada将继续专注于REL-P11用于代谢疾病的开发。
- Relmada资金充裕，截至2024年9月30日，现金及现金等价物约为$5410万。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间